Scenario description
Assume Eli Lilly does not have a U.S. retatrutide obesity/chronic weight-management BLA materially under FDA review by 2027-03-31 because the company delays submission beyond Q1 2027, withdraws or pauses a submitted application, receives or discloses a refusal-to-file or comparable major FDA filing obstacle, or submits a materially narrowed U.S. application that excludes the core obesity/chronic weight-management use described in the Phase 3 retatrutide reports. The initiating change is a setback to the expected U.S. regulatory path for retatrutide, with the reason potentially involving safety, tolerability, CMC/manufacturing, completeness of the clinical package, labeling strategy, or other regulatory-readiness issues. Exact deficiency details, if any, are not assumed beyond what Lilly or FDA reports by the cutoff.